This site is intended for healthcare professionals
Multiple Sclerosis (MS) Learning Zone
Declaration of sponsorship Novartis Pharma AG

Congresses

Declaration of sponsorship Novartis Pharma AG
Read time: 125 mins
Last updated:20th Dec 2021
Published:12th Aug 2021

Novartis has over 80 years of experience in the field of neurosciences, and is committed to developing innovative treatments and improving outcomes for people with MS – view the latest MS data and insights from experts in the Novartis Pharma AG-sponsored congress resources.

  • Your choice of over 40 Novartis Pharma AG-sponsored MS resources from international MS congresses in 2021 and 2020
  • View and download a diverse selection of oral presentations and ePosters
  • Access core MS data from the ASCLEPIOS and EXPAND Phase 3 clinical trials – start a data discussion with your colleagues

ECTRIMS 2021

View or download Novartis Pharma AG-sponsored multiple sclerosis (MS) research from the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and explore:

  • The latest ofatumumab data from the ASCLPEIOS I/II, APLIOS, APOLITOS, ALITHIOS, and KYRIOS clinical trials
  • Siponimod data from the EXPAND pivotal trial, including 7-year data on disability progression in patients with secondary progressive MS (SPMS)
  • Interactions between fatigue, cognition, pain, and depression in MS, the Phase 3 NEOS clinical trial study design for paediatric MS, and more

Ofatumumab efficacy and safety

Ofatumumab is a human anti-CD20 monoclonal antibody, indicated first-line for relapsing forms of MS (RMS). It was approved in 2021 by the European Medicines Agency (EMA)1.

Click the link to view a downloadable infographic of key ofatumumab data in ASCLEPIOS I and II pivotal trials

Below, view or download Novartis Pharma AG-sponsored ePosters from ECTRIMS 2021, reporting clinical trial data on the effect of ofatumumab on serum immunoglobulin levels and infection risk, on brain volume loss or microglia activation, or COVID-19 outcomes in patients with RMS. Clinical trials reported include ASCLPEIOS I and II, APLIOS, APOLITOS, ALITHIOS, and KYRIOS2–6.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

AAN 2021

Explore the Novartis Pharma AG-sponsored research on multiple sclerosis (MS) presented at the Annual Meeting of the American Academy of Neurology.

  • Download your choice of the latest subgroup and long-term extension study data from the Phase 3, Novartis Pharma AG-sponsored ASCLEPIOS and EXPAND clinical trials
  • Learn about ofatumumab treatment outcomes in people with RMS across different racial or ethnic groups in the ASCLEPIOS I/II and APOLITOS trials
  • What is the effect of siponimod on magnetic resonance imaging (MRI) measures of inflammation and neurodegeneration over time? Continue below to find out.

 The following resources from AAN 2021 focus on high-efficacy treatments (HETs) for multiple sclerosis (MS), ofatumumab and siponimod, as recently evaluated in the ASCLEPIOS I and II and EXPAND pivotal clinical trials2,8, respectively.

ASCLEPIOS2

Sponsored by Novartis Pharma AG, ASCLEPIOS I and II are randomised, Phase 3 trials, evaluating the HET ofatumumab versus teriflunomide in adults with relapsing-multiple sclerosis (RMS)2.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

EAN 2021

Extend your understanding of multiple sclerosis (MS) with the following selection of Novartis Pharma AG-sponsored presentations from EAN 2021.

  • Composite endpoints could reduce study sample sizes by more than 600 in future studies on secondary progressive multiple sclerosis (SPMS) – see the EXPAND trial presentation below
  • What outcomes and measures are most relevant to people living with MS? – view the presentation by Trishna Bharadia to deepen your knowledge

EXPAND8

Sponsored by Novartis Pharma AG, EXPAND is a double-blind, placebo-controlled, Phase 3 study comparing the efficacy and safety of the active high-efficacy therapy (HET) siponimod versus placebo in secondary-progressive multiple sclerosis (SPMS)8.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

AAN 2020

Match your own educational objectives with the Novartis Pharma AG-sponsored learning resources below from the AAN 2020.

  • Take the long-term view: access data from the core and extension parts of the ASCLEPIOS and EXPAND pivotal trials
  • Evidence shows that the high-efficacy therapy (HET) ofatumumab can maintain low-levels of B cells in people with relapsing multiple sclerosis (RMS)? – view the ASCLEPIOS data, below
  • Learn recent insights about glial fibrillary acidic protein (GFAP) as a treatment response marker in MS

AAN is the Annual Meeting of the American Academy of Neurology.

The following resources from the AAN 2020 focus on two HETs for multiple sclerosis (MS), ofatumumab and siponimod, as recently evaluated in the ASCLEPIOS I and II and EXPAND pivotal clinical trials2,8, respectively.

ASCLEPIOS2

Sponsored by Novartis Pharma AG, ASCLEPIOS I and II are randomised, Phase 3 trials, evaluating ofatumumab versus teriflunomide in adults with relapsing-multiple sclerosis (RMS)2.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

EAN 2020

The following MS-related resources are from EAN 2020. In line with the information presented in this Learning Zone, the educational materials below focus on the latest data from the Novartis Pharma AG-sponsored ASCELPIOS I and II2, and EXPAND8.

  • In the ASCLEPIOS and EXPAND Phase 3 clinical trials, there are differences in the treatment effect in different categories of participants. View the subgroup analyses in this section.
  • From the core and extension parts of the EXPAND trial, view long-term data of the high-efficacy therapy (HET) siponimod in people with secondary progressive multiple sclerosis (SPMS)
  • Are the sphingosine 1-phosphate receptor modulators a treatment option in COVID-19 induced acute respiratory distress syndrome (ARDS)? Read on

ASCLEPIOS2

Sponsored by Novartis Pharma AG, ASCLEPIOS I and II are randomised, Phase 3 trials, evaluating the HET ofatumumab versus teriflunomide in adults with relapsing-multiple sclerosis (RMS)2.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

ACTRIMS/ECTRIMS 2020

Explore Novartis Pharma AG-sponsored multiple sclerosis (MS) learnings from ACRTIMS/ECTRIMS 2020, the largest MS scientific conference in the world.

  • The PK-B cell model shows sustained B-cell depletion with the high-efficacy therapy (HET) ofatumumab – explore the data below
  • Are you aware that the HET siponimod can improve disability, cognitive processing speed, and relapse outcomes in people with active SPMS for up to 5 years? Learn more in this section.
  • Download, view, and play first-author narrations in our diverse MS resources

In 2020, the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual, went online to share the latest findings and progress in MS with over 8,000 MS experts from 100 countries.

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is the world’s largest professional organisation dedicated to the understanding and treatment of MS. The ECTRIMS annual congress occurs in a different city each year, and brings together MS experts from over the world to share new knowledge and insights about MS.

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is a community of leaders from the United States and Canada who are dedicated to the treatment and research in MS and other demyelinating diseases. Tri-annually ACTRIMS hosts a joint conference with ECTRIMS to discuss the latest findings and progress in MS, in addition to their annual forums.

ECTRIMS 2021 updates are coming soon to this Learning Zone – videos, publication digests, and an infographic) – look out for email and social media notifications

ASCLEPIOS2

Sponsored by Novartis Pharma AG, ASCLEPIOS I and II are randomised, Phase 3 trials, evaluating the HET ofatumumab versus teriflunomide in adults with relapsing-multiple sclerosis (RMS)2.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. European Medicines Agency (EMA). Kesimpta®. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta#product-information-section. Accessed 24 November 2021.
  2. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–557.
  3. Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2021;13524585211044480.
  4. Saida T, Nakahara J, Sazonov D V., Kurosawa T, Tsumiyama I, Willi R, et al. Sustained Efficacy of Ofatumumab in Relapsing Multiple Sclerosis Patients: Results from Extended Treatment in the Phase 2 APOLITOS Study (2032). Neurology. 2021;96(15 Supplement).
  5. ClinicalTrials.gov. Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS). 2021. https://clinicaltrials.gov/ct2/show/NCT03650114. Accessed 18 November 2021.
  6. ClinicalTrials.gov. Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab (KYRIOS). 2021. https://clinicaltrials.gov/ct2/show/NCT04869358. Accessed 18 November 2021.
  7. European Medicines Agency (EMA). Mayzent®. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent#product-information-section. Accessed 24 November 2021.
  8. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273.
  9. ClinicalTrials.gov. Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS). 2021. https://clinicaltrials.gov/ct2/show/NCT04926818. Accessed 18 November 2021.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: